A Phase 2 interventional study of Trastuzumab in Gastric Cancer, sponsored by Hoffmann-La Roche. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-08-11.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing trastuzumab in Stomach Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Trastuzumab · Stomach Neoplasms.
Among the 40 studies testing trastuzumab in Stomach Neoplasms, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2004, is one of 25 in phase 2, and was the 16th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →8 of the 40 studies testing trastuzumab in Stomach Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 20+
Xijing Hospital · Sites in China
Ages 18+
Zhejiang Cancer Hospital · Sites in China
Ages 18–75
Henan Cancer Hospital · Sites in China
Ages 18–75
Kangbuk Samsung Hospital · Sites in Korea, Republic of
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 3 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 40 across the 39 interventional studies. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 40 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
29 studies in Stomach Neoplasms by Hoffmann-La Roche: none open now, 2 under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2004, is one of 11 in phase 2, and was the 19th registered.
Hoffmann-La Roche’s Stomach Neoplasms studies by the year they started, since 2003.
1 of the studies testing trastuzumab in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06439550The First Affiliated Hospital of Zhengzhou UniversityAdjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing trastuzumab in Stomach Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 29 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of Herceptin in patients with metastatic or advanced gastric cancer with disease progression during platinum-based or 5-fluoropyrimidine-based chemotherapy. The anticipated time on study treatment is until disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
Drug: Trastuzumab
4 mg/kg initial dose, followed by 2 mg/kg
Also known as: Herceptin
Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category
Tumor response assessed according to RECIST. Complete response (CR): complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 millimeters \[mm\]); no new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable disease (SD): not qualifying for CR, PR, or progressive disease (PD). Participants who could not be classified per RECIST were allocated as follows: early death from malignant disease (death due to cancer), early death because of other cause (death not related to toxicity or cancer disease), and unknown (for not fitting into the above categories).
Time frame: Weekly throughout study
Percentage of Participants With Clinical Benefit
Participants were classified as having a clinical benefit if they had a best overall tumor response of CR, PR, or SD. Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable SD: not qualifying for CR, PR, or PD.
Time frame: Weekly throughout the study
Percentage of Participants With a Best Overall Response of CR or PR
Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions.
Time frame: Weekly throughout the study
Overall Survival - Number of Participants Who Died
OS was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
Time frame: Weekly throughout the study
Overall Survival
Overall survival (OS) was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
Time frame: Weekly throughout the study
Time to Progression - Number of Participants With an Event
Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
Time frame: Weekly throughout the study
Time to Progression
Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
Time frame: Weekly throughout the study
| Milestone | Trastuzumab Monotherapy |
|---|---|
| Started | 6 |
| Completed | 2 |
| Not completed | 4 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 1 |
| Withdrew: Changed to a different study | 1 |
| Withdrew: Sponsor decision | 1 |
Tumor response assessed according to RECIST. Complete response (CR): complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 millimeters \[mm\]); no new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable disease (SD): not qualifying for CR, PR, or progressive disease (PD). Participants who could not be classified per RECIST were allocated as follows: early death from malignant disease (death due to cancer), early death because of other cause (death not related to toxicity or cancer disease), and unknown (for not fitting into the above categories).
| percentage of participants | Trastuzumab Monotherapy |
|---|---|
| CR | 0 |
| PR | 33.3 |
| SD | 0 |
| PD | 50.0 |
| Early death from malignant disease | 0 |
| Early death because of other cause | 16.7 |
| Unknown | 0 |
Participants were classified as having a clinical benefit if they had a best overall tumor response of CR, PR, or SD. Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable SD: not qualifying for CR, PR, or PD.
| percentage participants | Trastuzumab Monotherapy |
|---|---|
| Percentage of Participants With Clinical Benefit | 33.3 |
Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions.
| percentage participants | Trastuzumab Monotherapy |
|---|---|
| Percentage of Participants With a Best Overall Response of CR or PR | 33.3 |
OS was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
| participants | Trastuzumab Monotherapy |
|---|---|
| Overall Survival - Number of Participants Who Died | 2 |
Overall survival (OS) was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
| months | Trastuzumab Monotherapy |
|---|---|
| Overall Survival | 6.39 (1.4 to 18.7) |
Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
| participants | Trastuzumab Monotherapy |
|---|---|
| Time to Progression - Number of Participants With an Event | 5 |
Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.
| months | Trastuzumab Monotherapy |
|---|---|
| Time to Progression | 1.78 (1.4 to 7.4) |
Collected over Weekly throughout the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab Monotherapy | — | 3/6 (50%) | 6/6 (100%) |
| Event | Trastuzumab Monotherapy |
|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/6 |
| General physical health deteriorationGeneral disorders | 1/6 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/6 |
| Renal failureRenal and urinary disorders | 1/6 |
| Stent placementSurgical and medical procedures | 1/6 |
| Oesophageal stent insertionSurgical and medical procedures | 1/6 |
| Oesophageal haemorrhageGastrointestinal disorders | 1/6 |
| HypersensitivityImmune system disorders | 1/6 |
| Event | Trastuzumab Monotherapy |
|---|---|
| Abdominal painGastrointestinal disorders | 3/6 |
| NauseaGastrointestinal disorders | 3/6 |
| DiarrhoeaGastrointestinal disorders | 2/6 |
| ChillsGeneral disorders | 2/6 |
| PyrexiaGeneral disorders | 2/6 |
| AscitesGastrointestinal disorders | 1/6 |
| ConstipationGastrointestinal disorders | 1/6 |
| DysphagiaGastrointestinal disorders | 1/6 |
| FlatulenceGastrointestinal disorders | 1/6 |
| RetchingGastrointestinal disorders | 1/6 |
Intent-to-treat (ITT) population: all participants who signed informed consent for the study.
| Age, Continuous(years) | Trastuzumab Monotherapy |
|---|---|
| Mean | 62.49 ± 9.79 |
| Sex: Female, Male(Participants) | Trastuzumab Monotherapy |
|---|---|
| Female | 1 |
| Male | 5 |
The record gives a start of Jan 2004, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 6 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab